07:00 , Oct 18, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetic cardiomyopathy Ceramide synthase 5 (CERS5; LASS5) Studies in cell culture and in mice suggest antagonizing CERS5 could be useful for treating diabetic cardiomyopathy....